This company has been acquired
Entasis Therapeutics Holdings Beheer
Beheer criteriumcontroles 2/4
Belangrijke informatie
Manos Perros
Algemeen directeur
US$2.0m
Totale compensatie
| Percentage CEO-salaris | 27.0% |
| Dienstverband CEO | 7.2yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 3yrs |
| Gemiddelde ambtstermijn bestuur | 4.3yrs |
Recente managementupdates
Recent updates
Will Entasis Therapeutics Holdings (NASDAQ:ETTX) Spend Its Cash Wisely?
Dec 16
Entasis Therapeutics: AstraZeneca Spin-Out Developing Targeted Antibacterial Products
Nov 17Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Aug 19Entasis Therapeutics shares rise after lining up ETX0462 poster presentation
Jun 18What Kind Of Shareholders Own Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX)?
Feb 17
Is Entasis Therapeutics Holdings (NASDAQ:ETTX) In A Good Position To Invest In Growth?
Dec 01Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2022 | n/a | n/a | -US$52m |
| Dec 31 2021 | US$2m | US$553k | -US$47m |
| Sep 30 2021 | n/a | n/a | -US$46m |
| Jun 30 2021 | n/a | n/a | -US$45m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$1m | US$537k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$46m |
| Mar 31 2020 | n/a | n/a | -US$46m |
| Dec 31 2019 | US$1m | US$495k | -US$44m |
| Sep 30 2019 | n/a | n/a | -US$38m |
| Jun 30 2019 | n/a | n/a | -US$52m |
| Mar 31 2019 | n/a | n/a | -US$44m |
| Dec 31 2018 | US$2m | US$450k | -US$42m |
| Sep 30 2018 | n/a | n/a | -US$43m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$35m |
| Dec 31 2017 | US$1m | US$430k | -US$30m |
| Dec 31 2016 | US$761k | US$413k | -US$19m |
Compensatie versus markt: De totale vergoeding ($USD 2.05M ) Manos } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).
Compensatie versus inkomsten: De vergoeding van Manos is gestegen terwijl het bedrijf verliesgevend is.
CEO
Manos Perros (54 yo)
7.2yrs
Tenure
US$2,047,687
Compensatie
Dr. Manoussos Perros, Ph D., also known as Manos, serves as the Chief Executive Officer, President & Director at Entasis Therapeutics Inc. Dr. Perros has been President, Chief Executive Officer and Directo...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.2yrs | US$2.05m | 0.17% $ 174.7k | |
| Chief Scientific Officer | 7.2yrs | US$998.39k | 0.098% $ 103.0k | |
| Chief Medical Officer | 2.7yrs | US$1.09m | 0.052% $ 54.7k | |
| Interim VP and Interim Principal Financial & Accounting Officer | less than a year | geen gegevens | geen gegevens | |
| General Counsel | 3.3yrs | geen gegevens | 0.35% $ 367.0k | |
| Chief Development Officer | 7.2yrs | US$754.14k | 0.35% $ 365.9k | |
| Chief Pharmaceutical Sciences & Manufacturing Officer | 1.8yrs | geen gegevens | 0.35% $ 367.0k | |
| Chief Commercial Officer | less than a year | geen gegevens | 0.26% $ 273.7k |
3.0yrs
Gemiddelde duur
55.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van ETTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 7.2yrs | US$2.05m | 0.17% $ 174.7k | |
| Independent Director | 4.3yrs | US$153.23k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | 1.9yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.9yrs | US$49.00k | geen gegevens | |
| Member of Scientific & Clinical Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific & Clinical Board | no data | geen gegevens | geen gegevens | |
| Independent Director | 2.9yrs | US$123.05k | 0.046% $ 48.2k | |
| Independent Director | 4.9yrs | US$132.33k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | no data | geen gegevens | geen gegevens | |
| Independent Chairman of the Board | 3.1yrs | US$174.28k | 0.046% $ 48.2k | |
| Member of Scientific & Clinical Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific & Clinical Board | no data | geen gegevens | geen gegevens |
4.3yrs
Gemiddelde duur
57.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van ETTX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).